Relay Therapeutics Raises $275M in Public Stock Offering
Event summary
- Relay Therapeutics priced a public offering of 22,916,667 shares of common stock at $12.00 per share, raising approximately $275 million.
- The offering includes a 30-day option for underwriters to purchase an additional 3,437,500 shares.
- The offering is expected to close on or about May 22, 2026, subject to customary closing conditions.
- Jefferies, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are joint book-running managers for the offering.
- Relay Therapeutics' lead clinical asset, zovegalisib, is currently in a Phase 3 clinical trial for HR+/HER2- metastatic breast cancer.
The big picture
Relay Therapeutics' $275 million public offering underscores the ongoing need for biotech companies to secure substantial capital to fund late-stage clinical trials and operational expansion. The move comes amid a competitive landscape where precision medicine firms are racing to bring innovative therapies to market, particularly in oncology and genetic diseases. The involvement of top-tier underwriters like Jefferies and Goldman Sachs signals confidence in Relay's pipeline, but the success of the offering will hinge on the company's ability to deliver on clinical milestones and maintain investor interest in a volatile biotech sector.
What we're watching
- Funding Utilization
- How Relay Therapeutics will allocate the $275 million proceeds to advance its clinical pipeline and operational scale.
- Market Performance
- Whether the public offering will stabilize or volatility in Relay Therapeutics' stock price post-listing.
- Clinical Milestones
- The pace at which zovegalisib and other pipeline assets progress through clinical trials, impacting long-term valuation.
Related topics